Effect of grapefruit juice on digoxin pharmacokinetics in humans

Clinical Pharmacology and Therapeutics

Volumn 70, Issue 4, 2001, Pages 311-316

  Becquemont, L ^a   Verstuyft, C ^a   Kerb, R ^a   Brinkmann, U ^a   Lebot, M ^a   Jaillon, P ^a   Funck Brentano, C ^a  

^a SORBONNE UNIVERSITÉ   (France)

Author keywords

[No Author keywords available]

Indexed keywords

DIGOXIN; GLYCOPROTEIN P;

ADULT; AREA UNDER THE CURVE; ARTICLE; BIOAVAILABILITY; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DRUG DISPOSITION; DRUG MECHANISM; DRUG TOLERABILITY; FEMALE; FOOD DRUG INTERACTION; FRUIT JUICE; GENETIC POLYMORPHISM; HUMAN; INGESTION; KIDNEY CLEARANCE; MALE; PRIORITY JOURNAL; PROTEIN TRANSPORT; RANDOMIZED CONTROLLED TRIAL;

AREA UNDER CURVE; BEVERAGES; CITRUS; CROSS-OVER STUDIES; DIGOXIN; FOOD-DRUG INTERACTIONS; GENOTYPE; HUMANS; P-GLYCOPROTEIN; POLYMORPHISM, GENETIC;

EID: 0034751938     PISSN: 00099236     EISSN: None     Source Type: Journal    
DOI: 10.1067/mcp.2001.118867     Document Type: Article

References (28)

1. Drug interactions with grapefruit juice
2. Grapefruit juice enhances the bioavailability of the HIV protease inhibitor saquinavir in man
3. Grapefruit juice increases serum concentrations of atorvastatin and has no effect on pravastatin
4. Grapefruit juice increases felodipine oral availability in humans by decreasing intestinal CYP3A protein expression
5. Identification of 6′, 7′-dihydroxybergamottin, a cytochrome P450 inhibitor, in grapefruit juice
6. 6′, 7′-Dihydroxybergamottin in grapefruit juice and Seville orange juice: Effects on cyclosporine disposition, enterocyte CYP3A4, and P-glycoprotein
7. Role of intestinal P-glycoprotein (mdr1) in interpatient variation in the oral bioavailability of cyclosporine
8. The contribution of P-glycoprotein to pharmacokinetic drug-drug interactions
9. Inhibition of P-glycoprotein-mediated drug transport: A unifying mechanism to explain the interaction between digoxin and quinidine
10. Molecular basis of cardiovascular drug metabolism: Implications for predicting clinically important drug interactions
11. Significance of P-glycoprotein for the pharmacology and Clinical use of HIV protease inhibitors
12. The role of intestinal P-glycoprotein in the interaction of digoxin and rifampin
13. Interrelationship between substrates and inhibitors of human CYP3A and P-glycoprotein
14. Modulators and substrates of P-glycoprotein and cytochrome P4503A coordinately up-regulate these proteins in human colon carcinoma cells
15. Drug-grapefruit juice interactions
16. Flavonoids: A class of modulators with bifunctional interactions at vicinal ATP- and steroid-binding sites on mouse P-glycoprotein
17. Inhibition of the CYP3A4-mediated metabolism and P-glycoprotein-mediated transport of the HIV-I protease inhibitor saquinavir by grapefruit juice components
18. Effect of furanocoumarin derivatives in grapefruit juice on the uptake of vinblastine by Caco-2 cells and on the activity of cytochrome P450 3A4
19. Oral bioavailability of digoxin is enhanced by talinolol: Evidence for involvement of intestinal P-glycoprotein
20. Effect of clarithromycin on renal excretion of digoxin: Interaction with P-glycoprotein
21. Longitudinal assessment of a P-glycoprotein-mediated drug interaction of valspodar on digoxin
22. Pharmacokinetic interaction of digoxin with an herbal extract from St John's wort (Hypericum perforatum)
23. Functional polymorphisms of the human multidrug-resistance gene: Multiple sequence variations and correlation of one allele with P-glycoprote in expression and activity in vivo
24. Pharmacokinetic and pharmacodynamic drug interactions between digoxin and macrogol 4000, a laxative polymer, in healthy volunteers
25. Assessment of CYP2D6 and CYP2C19 activity in vivo in humans: A cocktail study with dextromethorphan and chloroguanide alone and in combination
26. Improved sensitivity of digoxin assay by modification of the EMIT 2000 method
27. Atorvastatin coadministration may increase digoxin concentrations by inhibition of intestinal P-glycoprotein-mediated secretion
28. Induction of P-glycoprotein by rifampin increases intestinal secretion of talinolol in human beings: A new type of drug/drug interaction